A review of the treatment of drug induced presbyopia
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20231718Keywords:
Presbyopia, Medicine, AccommodationAbstract
Presbyopia is characterized by accommodative loss that leads to negative effects on vision-targeted health-related quality of life. It occurs in people who gradually lose the ability to adapt after the age of 40. Accommodation depends on the contraction of the ciliary muscle and the iris, the change and the convergence of the lens. The parasympathetic nervous system regulates the degree of contraction of the ciliary muscle and the iris necessary to alter the shape and position of the lens, and its stimulation is effective by activating the muscarinic receptors present in both structures. The hypothesis presented here suggests that patients with emmetropic presbyopia correct accommodation with pharmacotherapy that includes a combination of cholinergic drugs and non-steroidal anti-inflammatory drugs (NSAIDs). Topical treatment deals with drug combinations to modify one or more factors involved in the accommodative process and have been proposed to be instilled either monocular/ binocularly. Result shows para-sympathomimetic stimulation of parasympathetic innervation (accommodation) and NSAID: Prolonging the effect of the para-sympathomimetic action and modulates the accommodation. The drug combination restores near vision without affecting distance vision. It is important to note that the drug form used has no inflammatory effects or other side effects. Despite the lack of a completely well understood mechanism, pharmacological control of presbyopia seems to be a possible and very attractive alternative for presbyopia patients. The studies mentioned in this review are to be considered pilot investigations as they involve either a small number of subjects or are single case series.
Metrics
References
McDonnell PJ, Lee P, Spritzer K, Lindblad AS, Hays RD. Associations of presbyopia with vision-targeted health-related quality of life. Arch Ophthalmol. 2003;121(11):1577-81.
Croft MA, Glasser A, Kaufman PL. Accommodation and presbyopia. Int Ophthalmol Clin. 2001;41(2):33-46.
Glasser A. Accommodation: Mechanism and measurement. Ophthalmol Clin N Am. 2006;19(1):1-12.
Garner LF, Yap MK. Changes in ocular dimensions and refraction with accommodation. Ophthalmic Physiological Optics. 1997;17(1):12-7.
Koeppl C, Findl O, Kriechbaum K, Drexler W. Comparison of pilocarpine-induced and stimulus-driven accommodation in phakic eyes. Experimental Eye Res. 2005;80(6):795-800.
Pardue MT, Sivak JG. Age-related changes in human ciliary muscle. Optometr Vision Sci. 2000;77(4):204-10.
Croft MA, Kaufman PL, Erickson-Lamy K, Polansky JR. Accommodation and ciliary muscle muscarinic receptors after Echothiophate. Investigative Ophthalmol Visual Sci. 1991;32(13):3288-97.
Ostrin LA, Glasser A. Comparisons between pharmacologically and Edinger-Westphal-stimulated accommodation in rhesus monkeys. Investigative Ophthalmol Visual Sci. 2005;46(2):609-17.
Mathews S. Scleral expansion surgery does not restore accommodation in human presbyopia. Ophthalmology. 1999;106(5):873-7.
Koopmans SA, Terwee T, Barkhof J, Haitjema HJ, Kooijman AC. Polymer refilling of presbyopic human lenses in vitro restores the ability to undergo accommodative changes. Investigative Ophthalmol Visual Sci. 2003;44(1):250-7.
Wendt M, Glasser A. Topical and intravenous pilocarpine stimulated accommodation in anesthetized rhesus monkeys. Experimental Eye Researc. 2010;90(5):605-16.
Charman WN. Developments in the correction of presbyopia II: surgical approaches. Ophthalmic Physiological Optics. 2014;34(4):397-426.
Ostrin LA, Glasser A. Effects of pharmacologically manipulated amplitude and starting point on edinger-westphal-stimulated accommodative dynamics in rhesus monkeys. Investigative Ophthalmol Visual Sci. 2007;48(1):313-20.
Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Int J Ophthalmol. 2003;217(2):89-98.
Sruti A, Viral J. Extended depth of focus intraocular lenses for presbyopia. Curr Opin Ophthalmol. 2018;29:109.
Sheri R. AAO 2019: Topical Treatments for Presbyopia on the Horizon. Eye Care. 2019. Available https://www.practiceupdate.com/content/ aao-2019-topical-treatments-for-presbyopia-on-the-horizon/91112. Accessed on 12 January, 2023.
Renna A, Vejarano LF, De la Cruz E, Alió JL. Pharmacological treatment of presbyopia by novel binocularly instilled eye drops: Astudy. Ophthalmol Therapy, 2013;5(1):63-73.
Zimmerman TJ, Wheeler TM. Miotics: Side effects and ways to avoid them. Ophthalmology. 1982;89(1):76-80.
Fiorelli VM, Bhat P, Foster CS. Nonsteroidal anti-inflammatory therapy and recurrent acute anterior uveitis. Ocular Immunol Inflammation, 2010;18(2):116-20.
Jabs DA. Treatment of ocular inflammation. Ocular Immunol Inflammation. 2004;12(3):163-8.
Patel S, Salamun F, Matovic K. Pharmacological correction of presbyopia. Poster presented at the XXXI congress of the ESCRS. 2013. Amsterdam. Available at: http://escrs.org/amsterdam2013/ programme/posters-details.asp?id=19804. Accessed on 15 January, 2023.
Donofrio Angelucci D, Pinelli R, Vejarano LF. http://isrs. Presbyopia eye drop targets miosis and accommodation. In Journal of Refractive Surgery Outlook. 2016. Available at: http://aao.org/resources/february-2016. Accessed on 15 January, 2023.
Benozzi J, Benozzi G, Orman B. Presbyopia: A new potential pharmacological treatment. Med Hypothesis Discovery Innovation Ophthalmol J. 2012;1(1):3-5.
Vargas V, Vejarano F, Alió JL. Near Vision Improvement with the Use of a New Topical Compound for Presbyopia Correction: A prospective, consecutive interventional non-comparative clinical study. Ophthalmol Therapy. 2019;8(1):31-9.
